{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:41:52Z","timestamp":1791394912267,"version":"4.3.3"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clinthera.2017.05.347","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T17:32:19Z","timestamp":1496079139000},"page":"1104-1122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment"],"prefix":"10.1016","volume":"39","author":[{"given":"Anne-Priscille","family":"Trouvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Lloret-Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.05.347_bib1","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.pain.2011.06.017","article-title":"A New Definition of Neuropathic Pain","volume":"152","author":"Jensen","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic Pain: Diagnosis, Pathophysiological Mechanisms, and Treatment","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib3","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.pain.2011.09.014","article-title":"The Specific Disease Burden of Neuropathic Pain: Results of a French Nationwide Survey","volume":"152","author":"Attal","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of Chronic Pain with Neuropathic Characteristics in the General Population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic Pain in the General Population: A Systematic Review of Epidemiological Studies","volume":"155","author":"van Hecke","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib6","doi-asserted-by":"crossref","first-page":"e010364","DOI":"10.1136\/bmjopen-2015-010364","article-title":"Prevalence of Chronic Pain in the UK: A Systematic Review and Meta-Analysis of Population Studies","volume":"6","author":"Fayaz","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2017.05.347_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011091.pub2","article-title":"Venlafaxine for Neuropathic Pain in Adults","volume":"8","author":"Gallagher","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.05.347_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00131402-200112000-00002","article-title":"Gabapentin and Venlafaxine for the Treatment of Painful Diabetic Neuropathy","volume":"3","author":"Simpson","year":"2001","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2017.05.347_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jdiacomp.2007.03.010","article-title":"The Effect of Venlafaxine HCl on Painful Peripheral Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus","volume":"22","author":"Kadiroglu","year":"2008","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clinthera.2017.05.347_bib10","first-page":"33","article-title":"An Open-Label, Non-Randomized Comparison of Venlafaxine and Gabapentin as Monotherapy or Adjuvant Therapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy","volume":"3","author":"Eardley","year":"2010","journal-title":"J Pain Res"},{"issue":"1","key":"10.1016\/j.clinthera.2017.05.347_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdr045","article-title":"Efficacy of Venlafaxine for the Prevention and Relief of Oxaliplatin-Induced Acute Neurotoxicity: Results of EFFOX, a Randomized, Double-Blind, Placebo-Controlled Phase III Trial","author":"Durand","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib12","first-page":"192","article-title":"Evaluation of the Efficacy and Safety of Pregabalin, Venlafaxine, and Carbamazepine in Patients with Painful Diabetic Peripheral Neuropathy. A Randomized, Double-Blind Trial","volume":"19","author":"Razazian","year":"2014","journal-title":"Neurosciences. (Riyadh)"},{"key":"10.1016\/j.clinthera.2017.05.347_bib13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.apmr.2014.11.024","article-title":"Efficacy of Venlafaxine XR for the Treatment of Pain in Patients with Spinal Cord Injury and Major Depression: A Randomized, Controlled Trial","volume":"96","author":"Richards","year":"2015","journal-title":"Arch Phys Med Rehab"},{"key":"10.1016\/j.clinthera.2017.05.347_bib14","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00520-015-3009-x","article-title":"Efficacy of Venlafaxine for the Relief of Taxane and Oxaliplatin-Induced Acute Neurotoxicity: A Single-Center Retrospective Case-Control Study","volume":"24","author":"Kus","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2017.05.347_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for Neuropathic Pain in Adults: A Systematic Review and Meta-Analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib16","first-page":"5","article-title":"Imipramine for Neuropathic Pain in Adults","author":"Hearn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.05.347_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011605","article-title":"Nortriptyline for Neuropathic Pain in Adults","volume":"1","author":"Derry","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.05.347_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011603","article-title":"Amitriptyline for Neuropathic Pain in Adults","volume":"7","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.05.347_bib19","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1161\/STROKEAHA.115.010259","article-title":"Management of Central Poststroke Pain: Systematic Review of Randomized Controlled Trials","volume":"46","author":"Mulla","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2017.05.347_bib20","first-page":"4","article-title":"Antidepressants for Neuropathic Pain","author":"Saarto","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.05.347_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2165\/00003495-199549020-00010","article-title":"Venlafaxine. A Review of Its Pharmacology and Therapeutic Potential in Depression","volume":"49","author":"Holliday","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2017.05.347_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0304-3959(03)00168-4","article-title":"Evidence for a Monoamine Mediated, Opioid-Independent, Antihyperalgesic Effect of Venlafaxine, a Non-Tricyclic Antidepressant, in a Neurogenic Pain Model in Rats","volume":"103","author":"Marchand","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib23","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1517\/14656566.2010.507192","article-title":"A Review of SSRIs and SNRIs in Neuropathic Pain","volume":"11","author":"Lee","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2017.05.347_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000345035","article-title":"Venlafaxine and Neuropathic Pain","volume":"91","author":"Cegielska-Perun","year":"2013","journal-title":"Pharmacology"},{"key":"10.1016\/j.clinthera.2017.05.347_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.nbd.2008.11.003","article-title":"Beta2-Adrenoceptors Are Essential for Desipramine, Venlafaxine or Reboxetine Action in Neuropathic Pain","volume":"33","author":"Yalcin","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.clinthera.2017.05.347_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/01.j.pain.0000460313.73358.31","article-title":"Intrathecal Reboxetine Suppresses Evoked and Ongoing Neuropathic Pain Behaviours by Restoring Spinal Noradrenergic Inhibitory Tone","volume":"156","author":"Hughes","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.brainres.2004.02.041","article-title":"Blockade of Supraspinal 5-HT1A Receptors Potentiates the Inhibitory Effect of Venlafaxine on Wind-up Activity in Mononeuropathic Rats","volume":"1008","author":"Marchand","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2017.05.347_bib28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejphar.2014.04.046","article-title":"Antinociceptive Effects of Venlafaxine in a Rat Model of Peripheral Neuropathy: Role of alpha2-Adrenergic Receptors","volume":"738","author":"Hajhashemi","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nbd.2013.08.012","article-title":"Antidepressants Suppress Neuropathic Pain by a Peripheral \u03b22-Adrenoceptor Mediated Anti-TNF\u03b1 Mechanism","volume":"60","author":"Bohren","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.clinthera.2017.05.347_bib30","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1097\/j.pain.0000000000000622","article-title":"Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan","volume":"157","author":"Miki","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/AJP.0b013e318159f94a","article-title":"Mirtazapine decreases the pain feeling in healthy participants","volume":"24","author":"Arnold","year":"2008","journal-title":"Clin J Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib32","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.jpainsymman.2009.11.311","article-title":"Effectiveness of mirtazapine in the treatment of postherpetic neuralgia","volume":"39","author":"Christodoulou","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2017.05.347_bib33","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1212\/WNL.57.9.1583","article-title":"Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain","volume":"57","author":"Semenchuck","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.05.347_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2125.1996.tb00173.x","article-title":"Venlafaxine Oxidation in Vitro Is Catalysed by CYP2D6","volume":"41","author":"Otton","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00007691-200004000-00011","article-title":"Venlafaxine Serum Levels and CYP2D6 Genotype","volume":"22","author":"Veefkind","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2017.05.347_bib36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","article-title":"O- and N-Demethylation of Venlafaxine in Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants","volume":"20","author":"Fogelman","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2017.05.347_bib37","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/j.1552-4604.1992.tb03875.x","article-title":"Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and Its Active O-Desmethyl Metabolite","volume":"32","author":"Klamerus","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/00498259309057023","article-title":"Metabolic Disposition of 14C-Venlafaxine in Mouse, Rat, Dog, Rhesus Monkey and Man","volume":"23","author":"Howell","year":"1993","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2017.05.347_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00023210-200115080-00007","article-title":"Venlafaxine Extended-Release: A Review of Its Use in the Management of Major Depression","volume":"15","author":"Wellington","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2017.05.347_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/138920021601150702160728","article-title":"Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription","volume":"16","author":"Lloret-Linares","year":"2015","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2017.05.347_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/026988110201600413","article-title":"Venlafaxine: The Relationship between Dose, Plasma Concentration and Clinical Response in Depressive Patients","volume":"16","author":"Charlier","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-003-0710-3","article-title":"Time Course of Clinical Response to Venlafaxine: Relevance of Plasma Level and Chirality","volume":"59","author":"Gex-Fabry","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/FTD.0b013e3181fcf94d","article-title":"Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine","volume":"33","author":"McAlpine","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2017.05.347_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/eujp.2001.0266","article-title":"Venlafaxine in Neuropathic Pain Following Treatment of Breast Cancer","volume":"6","author":"Tasmuth","year":"2002","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib45","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1212\/01.WNL.0000058749.49264.BD","article-title":"Venlafaxine versus Imipramine in Painful Polyneuropathy: A Randomized, Controlled Trial","volume":"60","author":"Sindrup","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.05.347_bib46","first-page":"131","article-title":"Venlafaxine in the Treatment of Atypical Facial Pain: A Randomized Controlled Trial","volume":"18","author":"Forssell","year":"2004","journal-title":"J Orofac Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.pain.2004.05.010","article-title":"Venlafaxine Extended Release in the Treatment of Painful Diabetic Neuropathy: A Double-Blind, Placebo-Controlled Study","volume":"110","author":"Rowbotham","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejpain.2004.09.009","article-title":"The Effect of Venlafaxine on Ongoing and Experimentally Induced Pain in Neuropathic Pain Patients: A Double Blind, Placebo Controlled Study","volume":"9","author":"Yucel","year":"2005","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2017.05.347_bib49","first-page":"321","article-title":"Effects of Venlafaxine and Carbamazepine for Painful Peripehral Diabetic Neuropathy\u202f: A Randomized, Double-Blind and Double-Dummy, Controlled Multi-Center Trial","volume":"6","author":"Jia","year":"2006","journal-title":"Chin J Evid-Based Med"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2017.05.347_bib50","doi-asserted-by":"crossref","first-page":"307s","DOI":"10.1016\/S0924-9338(97)83310-X","article-title":"A Review of the Efficacy and Tolerability of Venlafaxine","volume":"12","author":"Dierick","year":"1997","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.clinthera.2017.05.347_bib51","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.clinthera.2017.05.347_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12871-015-0150-5","article-title":"Clinical Practice Guidelines for the Management of Neuropathic Pain: A Systematic Review","volume":"16","author":"Deng","year":"2016","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib53","article-title":"Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review","volume":"2016","author":"Aiyer","year":"2016","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2017.05.347_bib54","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2125.2007.02849.x","article-title":"Cardiovascular Toxicity due to Venlafaxine Poisoning in Adults: A Review of 235 Consecutive Cases","volume":"64","author":"Howell","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hup.834","article-title":"Cardiovascular Effects of High Dose Venlafaxine XL in Patients with Major Depressive Disorder","volume":"22","author":"Mbaya","year":"2007","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.clinthera.2017.05.347_bib56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","article-title":"Applications of CYP450 Testing in the Clinical Setting","volume":"17","author":"Samer","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.clinthera.2017.05.347_bib57","first-page":"395","article-title":"Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review","volume":"18","author":"Beakley","year":"2015","journal-title":"Pain Physician"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817306458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817306458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T02:42:03Z","timestamp":1569379323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817306458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0149291817306458"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.05.347","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727671372.793556107","asserted-by":"object"}]},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.05.347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}